A lipoprotein lipase activator
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

NO-1886

Item No. 17425

Technical Information
Formal Name
[[4-[[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl]-phosphonic acid diethyl ester
CAS Number
133208-93-2
Synonyms
  • Ibrolipim
  • Lipoprotein Lipase Activator
  • LPL Activator
  • OPF 009
Molecular Formula
C19H20BrN2O4P
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 25 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 25 mg/mlEthanol: 2 mg/ml
λmax
260 nm
SMILES
BrC1=CC(C#N)=C(NC(C2=CC=C(CP(OCC)(OCC)=O)C=C2)=O)C=C1
InChi Code
InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)
InChi Key
KPRTURMJVWXURQ-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    NO-1886 is an LPL activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle.1 This coincides with an elevation in post-heparin plasma LPL activity and LPL mass in rats.1,2 NO-1886 decreases plasma triglyceride concentration and increases plasma high-density lipoprotein cholesterol, resulting in inhibited development of atherosclerotic lesions in coronary arteries and aortas of rats and rabbits.1,2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Yin, W., and Tsutsumi, K. Lipoprotein lipase activator NO-1886. Cardiovasc. Drug Rev. 21(2), 133-142 (2003).

    2. Tsutsumi, K., Inoue, Y., Shima, A., et alThe novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J. Clin. Invest. 92(1), 411-417 (1993).